Ending Plague

by Francis W. Ruscetti

  CNN’s Sanjay Gupta appeared taken aback in a new interview as former CDC Director Robert Redfield shared his “opinion” on the origins of COVID-19.

  Gupta spoke with Redfield as part of a new CNN documentary about the COVID-19 pandemic, and the former CDC chief revealed he thinks it’s likely the coronavirus originated in a Wuhan lab and was possibly being transmitted in September 2019.

  “If I was to guess, this virus started transmitting somewhere in September, October in Wuhan,” Redfield said. “That’s my own view. It’s only an opinion. I’m allowed to have opinions now.”

  Redfield continued that he thinks the “most likely etiology of this pathogen in Wuhan was from a laboratory, you know, escaped,” though he said he’s not “implying any intentionality” and reiterated “it’s my opinion.”14

  Is it just me, or when you read that section does it seem like the former director of the CDC is pathetically pleading not to be the next victim of cancel culture, or worse yet, vilified by the powers that be, and completely lose his status?

  Redfield knew, said, and did nothing when he worked on Trump’s task force, and then lied for a year while millions of lives were ruined. He also coauthored a February 1, 2020 article with Anthony Fauci saying that masks don’t work.

  I wish I could come up with some way to show my supreme disrespect for this kind of cowardice, but I think I’ll just let you use your imagination.

  ***

  The average person might reasonably ask, what is to be done?

  I’m telling you what I’m doing. I’m trying to get to the bottom of this controversy. I don’t think that China is solely to blame for this problem, but the United States is as well. It doesn’t matter where the viruses originally came from. Immortalized cell lines containing many unsuspected viruses have been shipped around the world for more than a quarter of a century.

  We need to STOP all this research and declare a moratorium on all vaccinations on the schedule until the animal and human aborted fetal tissue is removed and the double-blind placebo-controlled studies are done.

  The next step is to remove the serial felons and liars from the public health organizations and restore liability and informed consent for all pharmaceuticals, including vaccines.

  What I’ve tried to convey in this book is that there’s a scientific elite that exists above presidents and prime ministers, and they genuinely refuse to reveal the truth of what they’re doing in their labs, even to their own leaders. The president of China is probably in the dark just as much as our own leaders about what actually happened. I have tried to make this transparent to the general public by writing these books because I believe we, as scientists, are public servants, and you, the general public, deserve to know what’s happening in these labs.

  The spirit in which I write this book is in accord with the declaration by President Abraham Lincoln during the darkest days of our Civil War that: “I am a firm believer in the people. If given the truth, they can be depended upon to meet any national crisis. The great point is to bring them the real facts.”

  Toward that end, with the help of attorney Larry Klayman and his organization, Judicial Watch, I have joined their class action as an expert witness against the government of China, the People’s Liberation Army, and the Wuhan Institute of Virology for their role in the COVID-19 crisis and to discover the truth. From the opening of the action which was filed in the United States District Court for the Northern District of Texas on March 17, 2020:

  1. This is a complaint for damages and equitable relief arising out of the creation and release, accidental or otherwise, of a variation of coronavirus known as COVID-19 by the People’s Republic of China and its agencies and officials as a biological weapon in violation of China’s agreement under international treaties, and recklessly or otherwise allowing its release from the Wuhan Institute of Virology into the city of Wuhan, China, in Hubei Province, by among other acts failing to prevent the Institute’s personnel from becoming infected with the bioweapon and carrying it into the surrounding community and proliferation into the United States.

  2. Since biological weapons have been outlawed since at least 1925, including by China’s membership in treaties, these illegal weapons constitute and are in effect terrorist-related weapons of mass destruction of population centers.15

  Many have warned me against taking such bold, public action, but I am a woman of faith and fear only the Lord. We are not promised a life free of suffering. I look forward to a life in eternity, hearing the words, “Well done, good and faithful servant.” We all deserve the truth from our leaders and the best health that science can give us. We have a God given immune system that can defend us from disease, no matter what is created in laboratories. The Lord has given us a great abundance on this earth to keep us healthy. He has not left us defenseless in this time of terror.

  It’s up to each one of us to maintain the purity of our body temples, as created by God. The mark of the beast is not the needle in the arm. It’s the fear in the mind that causes us to doubt.

  We have all been deceived. But each of us can repent and change our hearts and minds, never allowing ourselves to fall into the trap of fear and hatred like COVID-19 again.

  Forgive yourself and forgive others.

  The obligation of a scholar, and indeed every citizen, is to discover the truth, speak the truth, and live in truth. I hope that through my efforts and example I have helped shed light on some very dark places in science and encouraged a healthy resurgence of true, unbiased science.

  If I have brought light to these issues, then perhaps I will have enhanced my fervent wish that the best of health finds its way to all of us.

  Notes

  PART ONE

  Chapter Two

  1 F.W. Ruscetti and P.A. Chervenick, “Release of Colony Stimulating factor from monocytes by Endotoxin and Poyino-Sinic-Polycytidic Acid,” Journal of Laboratory and Clinical Medicine 83 (January 1974) 64-72.

  2 F.W. Ruscetti, P.A. Chevernick, “The Release of Colony-Stimulating Factor from Thymus-Derived Lymphocytes,” Journal of Laboratory and Clinical investigation 55 (March 1975) 520-527.

  3 F.W. Ruscetti, R. Cypress, and P.A. Chevernick, “Specific release of Neutrophil and Eosinophil Stimulating Factors from Sensitized Lymphocytes,” Blood 47 (May 1976) 757-765.

  4 Norman Wolmark, “In Memoriam: Bernard Fisher, 1918-2019,” Journal of Clinical Oncology, 38. No. 16 (April 14, 2020), 1751-1756, www.doi.org/.1200/JCO.19.03299.

  Chapter Three

  1 Nicholas Wade, “Special Virus Cancer Program: Travails of a Biological Moon Shot,” Science, no. 4106 (December 24, 1971): 1306-1311.

  2 R.E. Gallagher and R. Gallo, “Type C RNA Tumor Virus Isolated from Cultured Human Acute Myelogous leukemia Cells,” Science, 187 (January 31, 1975): 350-353, www.doi.org/1o.1126/sceince.46123.

  3 N.M. Teich, R.A. Weiss, S.Z. Salahuddin, R.E. Gallagher, and R.C. Gallo, “Infective Transmission and Characterisation of a C-Type Virus Release by Cultured Human Myeloid Leukemia Cells,” Nature 256 (5518), (August 14, 1975): 55-1-555, www.doi.org/10.1038/256551a0.

  4 D.A. Morgan, F.W. Ruscetti, and R.C. Gallo, “Growth of Thymus-Derived Lymphocytes from Normal Human Bone Marrow,” Science 193 (1976) 1007-1008, F.W. Ruscetti, D.A. Morgan, and R.C. Gallo, “Functional and Morphological Characteristics of Human Thymus-Derived Lymphocytes Continuously Growing in Vitro,” Journal of Immunology 119 (July 1977) 131-138,

  5 R. Gallo, W. Saxinger, R. Gallagher, et al., “Some Ideas on the Origin of Human Leukemia in Man and Recent Evidence for the Presence of Type-C Related Viral Information,” Origins of Human Cancer, Cold Spring Press (Cold Springs Harbor, New York - 1977), p. 1253-1265.

  6 S. Gillis, P. E. Baker, F. W. Ruscetti, and K. A. Smith, “Long Term Culture of Human Antigen-Specific Cytotoxic T-Cell Lines,” Journal of Experimental Medicine, Vol. 148 (4), pp. 1093-1098: doi:10.1084/jem.148.4.1093.

  7 Ibid.

  8 Ibid at 1093.

  9 Steve Rosenbe
rg, “IL-2: The First Effective Immunotherapy for Human Cancer,” Journal of Immunology, Vol. 192, (12), pp. 5451-5458, 5451: doi: 10.4049/jimmunol.1490119.

  10 American Association of Immunology Meeting in Honolulu, Hawaii, www.drive.google.com/file/d/1CS7MV5q3BoHz-4usxe4HlNsVdrK-1g1J/view

  11 S. Collins, F. Ruscetti, F. Gallagher, and R. Gallo, “Terminal Differentiation of Human Promyelocytic Leukeima Cells Induced by Dimethyl Sulfide and Other Polar Compounds,” Proceedings of the National Academy of Sciences 75 (May 1978) 2458-2462, www.doi.org/10.1073.pnas.75.5.2458.

  12 T.R. Breitman, Stuart E. Selonick, and Steven J. Collins, “Induction of Differentiation of the Human Promyelocytic Leukemia Cell Line (HL-60) by Retinoic Acid,” Proceedings of the National Academy of Sciences 77, no. 5 May 1980): 2936-2940.

  13 “Blood Flashback – 1979: Characterization of the Continuous Differentiating Myeloid Cell Line (HL-60) From a Patient with Acute Promyelotic Leukemia,” American Society of Hematology, (2016): www.doi.org/10.1182/blood-2016-10-748780.

  14 A.F. Gazdar, D.N. Carney. P.A. Bunn, E.K. Russel, E.S. Jaffe, G.P. Schechter, and J.G. Guccion, “Mitogen Requirements for the In Vitro Propogation of Cutaneous T-Cell Lymphomas,” Blood 55, no. 3 (March 1980): 409-417.

  15 B. Poiesz, F.W. Ruscetti, A. Gazdar, et al., “Isolation of Type-C Retrovirus particles from Cultured and Fresh Lymphocytes from a Patient with Cutaneous T-Cell Lymphoma,” Proceedings of the National Academy of Sciences 77 (December 1980) 7415-7419. www.doi.org/10.1073/pnas.77.12.7415.

  16 John M. Coffin, “The Discovery of HTLV-1, the First Pathogenic Human Retrovirus,” Proceedings of the National Academy of Sciences 51, 15525 – 15529, www.doi.org/10.1073/pnas.1521629112.

  17 S.Z. Salahuddin, P.D. Markham, F.W. Ruscetti, R.C. Gallo, “Long-Term Suspension Cultures of Human Cord Blood Myeloid Cells,” Blood 58 (November 1981) 931-938, www.doi.org/10.1182/blood.V58.5.931.931.

  18 J.E. Gootenberg, F.W. Ruscetti, J.W. Mier, et al., “Human Cutaneous T-Cell Lymphoma Lines Produce and Respond to T-Cell Growth Factor,” Journal of Experimental Medicine 154 (November 1981) 1403-1418, www.doi.org/10.1084/jem.154.5.1403.

  19 J.E. Gootenberg, F.W. Ruscetti, R.C. Gallo, “A Biochemical Variant of T-Cell Growth Factor from a Human T-Cell Lymphoma Line,” Journal of Immunology 129 (October 1982) 1499-1505.

  Chapter Four

  1 Robert K. Merton, “The Matthew Effect in Science,” Science 159, 56-63 (January 5, 1968): 56-63. www.doi.org/10.1126/science.159.3810.56.

  2 Nicholas Wade, “Special Virus Cancer Program: Travails of a Biological Moon Shot,” Science, no. 4106 (December 24, 1971): 1306-1311.

  Chapter Five

  1 Aldous Huxley, Complete Essays, Vol. II: 1926-1929 (Chicago: Ivan Dee, 2000), (Notes on Dogma)

  2 Macbeth, Act 3, Scene 2, Page 3.

  3 L. Wolff and S. Ruscetti, “Malignant Transformation of Erythroid Cells In Vivo by Introduction of a Non-Replicating Retrovirus Vector,” Science 228 (June 28, 1985): 1549-1552, www.doi.org/10.1126/science.2990034.

  4 F. Barré-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Daugert, C-Axler-Blin, F. Vezinet-Brun, C. Rouziox, W. Rosenbaum, and L. Montagnier, “Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS),” Science 22, (May 20, 1983): 868-871, www.doi.org/10.1126/science.6189183.

  5 R.C. Gallo, P.S. Sarin, E.P. Gelmann, M. Robert-Guroff, E. Richardson, V.S. Kalyanaraman, D. Mann, G.D. Sidhu, R.E. Stahl, S. Zolla-Pazner, J. Leibowitch, and M. Popovic, “Isolation of Human T-Cell leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS),” Science 220 (May 20, 1983): 865-867, www.doi.org/10.1126/science.6601823.

  6 J.A. Levy, A.D. Hoffman, S.M. Kramer, J.A. Landis, J.M. Shimabukuro, and L.S. Oshiro, “Isolation of Lymphocytopathic Retroviruses from San Francisco Patients with AIDS,” Science 225 (August 24, 1984): 840-842, www.doi.org/10.1126/science.6206563.

  7 R.C. Gallo, P.S. Sarin, E.P. Gelmann, M. Robert-Guroff, E. Richardson, V.S. Kalyanaraman, D. Mann, G.D. Sidhu, R.E. Stahl, S. Zolla-Pazner, J. Leibowitch, and M. Popovic, “Isolation of Human T-Cell leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS),” Science 220 (May 20, 1983): 865-867, www.doi.org/10.1126/science.6601823.

  8 Serge Lang. “The Gallo Case,” (1989), pp. 364 – 632, 585 www.link.springer.com/content/pdf/10.1007%2F978-1-4612-1638-4_5.pdf.

  9 Ibid. at p. 490.

  10 Philip J. Hilts, “Federal Inquiry Finds Misconduct by a Discoverer of the AIDS Virus,” New York Times, December 31, 1992, www.nytimes.com/1992/12/31/us/federal-inquiry-finds-misconduct-by-a-discoverer-of-the-aids-virus.html.

  Chapter Six

  1 Society for Immunotherapy of Cancer, “Leading Cancer Immunotherapy Scientists and Teams,” October 4, 2010, www.sitcancer.org/aboutsitc/press-releases/2010/leading-scientists.

  2 Austin Frakt, “Reagan, Deregulation and America’s Exceptional Rise in Health Care Costs,” New York Times, June 4, 2018, www.nytimes.com/2018/06/04/upshot/reagan-deregulation-and-americas-exceptional-rise-in-health-care-costs.html

  3 Olivia Campbell, “Here’s What Happened when Reagan Went After Healthcare Programs. It’s Not Good,” Timeline, September 13, 2017, www.timeline.com/reagan-trump-healthcare-cuts-8cf64aa242eb.

  4 Ibid.

  5 Ibid.

  6 Ray Sipherd, “The third leading Cause of Death in US Most Doctors Don’t Want to Talk About,” CNBC, February 22, 2018, www.cnbc.com/2018/02/22/medical-errors-third-leading-cause-of-death-in-america.html

  7 Leah Sittile, “Living Sick and Dying Young in Rich America,” The Atlantic, December 19, 2013, www.theatlantic.com/health/archive/2013/12/living-sick-and-dying-young-in-rich-america/282495/

  8 Alan L. Hillman, David B. Nash, William L. Kissick, and Samuel P. martin, “Managing the Medical Industrial Complex,” New England Journal of Medicine 315 (August 21, 1986): 511-513, www.doi.org/10.1056/NEJM198608213150810.

  9 Alexader Zaitchik, “How Big Pharma was Captured by the One Percent,” The New Republic, June 28, 2018, www.newrepublic.com/article/149438/big-pharma-captured-one-percent

  10 Ibid.

  11 Ibid.

  12 Andrew Pollack and Michael. J. de la Merced, “Gilead to Buy Pharmasset for $11 Billion,” The New York Times, November 21, 2011, www.dealbook.nytimes.com/2011/11/21/gilead-to-buy-pharmasset-for-11-billion/

  13 P. Gosselin, “How the $250 Billion US Diabetes Industry Operates … There’s a Lot of money to be Made Keeping You Sick,” No Tricks Zone, January 2, 2016, www.notrickszone.com/2016/01/02/how-the-250-billion-us-diabetes-industry-operates-theres-a-lot-of-money-to-be-made-keeping-you-sick/

  14 Nora D. Volkow, “The Biology and Potential Therapeutic Effects of Cannabidol,” National Institute on Drug Abuse, June 24, 2015, www.archives.drugabuse.gov/testimonies/2015/biology-potential-therapeutic-effects-cannabidiol

  15 Arnold Relman, Marcia Angel, “America’s Other Drug Problem,” New Republic, (December 12, 2002), www.newrepublic.com/article/66623/americas-other-drug-problem

  16 Marcia Angell, “Drug Companies & Doctors: A Story of Corruption,” The New York Review of Books, January 15, 2009, www.nybooks.com/articles/2009/01/15/drug-companies-doctorsa-story-of-corruption/

  17 “Opioid Overdose Tops List of Leading Causes of Death in the U.S.” American Society of Hematological Clinical News, January 18, 2019, www.ashclinicalnews.org/online-exclusives/opioid-overdose-tops-list-leading-causes-death-u-s/

  18 Robert Pear, “Reagan Signs Bill on Drug Exports and Payment for Vaccine Injuries,” New York Times, November 15, 1986, www.nytimes.com/1986/11/15/us/reagan-signs-bill-on-drug-exports-and-payment-for-vaccine-injuries.html

  19 Jacob Hornberger, “The CIA’s Longstanding relationship with Crime,” Future of Freedom Foundation, August 13, 2020, www.fff.org/2020/08/13/the-cias-longstanding-relationship-with-crime/

  20 Landmark Recovery Staff, “The History of the War on Drugs: Reagan Era and Beyond,” Landmark Recovery, February 13, 2019, www.landmarkrecover
y.com/history-of-the-war-on-drugs-reagan-beyond/

  21 Harvey J. Alter and Harvey G. Klein, “The Hazards of Blood Transfusion in Historical Perspective,” Blood 112 (October 1, 2008): 2617-2626, www.doi.org/10.1182/blood-2008-07-077370.

  22 P.M. Hoffman, B.W. Festoff, L.T. Giron, Jr., L.C. Hollenbeck, R.M. Garruto, and F.W. Ruscetti, “Isolation of LAV/HTLV-III from a Patient with Amyotrophic Lateral Sclerosis,” New England Journal of Medicine 313 (August 1, 1985): 324-325, www.doi.org/10.1056/NEJM198508013130511.

  23 J.L. Marx, “Lasker Award Stirs Controversy,” Science 203, (January 26, 1979): 341, www.doi.org/10.1126/sicence.216074.

  24 Paul Trachtman, “Review of ‘Molecules of Emotion,’ book by Candace Pert,” Smithsonian Magazine, September 1998, www.smithsonianmag.com/arts-culture/review-of-molecules-of-emotion-157256854/#:~:text=In%20Molecules%20of%20Emotion%2C%20Pert,obscures%20the%20pursuit%20of%20truth.

  25 Ibid.

  26 Maria T. Polianova, Francis W. Ruscetti, Candace B. Pert, and Michael Ruff, “Chemokine receptor-5 (CCR5) is a receptor for the HIV Entry Inhibitor Peptide T (DAPTA), Journal of Antiviral Resistance, 67 (August 2005): 83-92, www.doi.org/10.1016/j.antiviral.2005.03.007.

  27 Hyeryun Choe, Michael Farzan, Ying Sun, Norma Gerard, raig Gerard, and Joseph Sodroski, “The B-Cemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates,” Cell 85 (June 28, 1996), 1135-1148, www.doi.org/10.1016/S0092-8674(00)81313-6.

  28 Julie Catusse, Chris M. parry, David R. Dewin, and Ursula A. Gompels, “Inhibition of HIV-1 Infection by Viral Chemokine U83A via High Affinity CCR5 Interactions that Block Human Chemokine-Induced Leukocyte Chemotaxis and Receptor Internalization,” Blood 109 (January 5, 2007): 3633-3639, www.doi.org/10.1182/blood-2006-08-042622.

  29 Mary T. Joy, Einor Ben Assayag, Dalia Shabashov-Stone, et al., “CCR5 is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury,” Cell 176 (February 21, 2019); 1143-1157, www.doi.org/10.1016/j.cll.2019.01.044.